CN107802689A - Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer - Google Patents
Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer Download PDFInfo
- Publication number
- CN107802689A CN107802689A CN201610805445.6A CN201610805445A CN107802689A CN 107802689 A CN107802689 A CN 107802689A CN 201610805445 A CN201610805445 A CN 201610805445A CN 107802689 A CN107802689 A CN 107802689A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- prostate cancer
- seed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/10—Peat; Amber; Turf; Humus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of application of Chinese medicine composition in the medicine for preparing treatment prostate cancer, the active ingredient of the Chinese medicine composition is mainly prepared by the raw material of following parts by weight：300~500 parts of the seed of cowherb, 350~580 parts of the Radix Astragali, 200~300 parts of plantain seed, 250~420 parts of CORTEX PHELLODENDRI AMURENE, 250~420 parts pointed at both ends, 250~420 parts of dandelion, 250~420 parts of Herba Lycopi, 55~95 parts of amber, 0.7~1.2 part of cinnamon oil, 1.2~2 parts of oil of badian.Found by drug efficacy study：Medicine containing above-mentioned Chinese medicine composition is respectively provided with certain inhibitory action to prostate gland cancer cell such as PC 3,22RV1, DU145, especially more obvious to PC 3 inhibition.Therefore above-mentioned Chinese medicine composition has the effect for the treatment of prostate cancer, thus provides the new application of the Chinese medicine composition, also provides new medicine for treatment prostate cancer.
Description
Technical field
The present invention relates to application in TCM field, more particularly to Chinese medicine composition in the medicine for treating prostate cancer is prepared
Application.
Background technology
Prostate cancer is to betide the malignant tumour in human male prostate tissue, is the extremely unordered life of prostatic acini cell
Long result.The incidence of disease of prostate cancer has obvious geographical and racial difference.In developed countries and regions such as America and Europes, it is
The most common malignant tumour of male, its death rate occupy the second of various cancers；In Asia, its incidence of disease is less than western countries,
But it is in rapid ascendant trend in recent years.
Qianlietong tablets record in《Pharmacopoeia of People's Republic of China》2015 editions one, main component includes the seed of cowherb, yellow
Stilbene, plantain seed, CORTEX PHELLODENDRI AMURENE is pointed at both ends, dandelion, Herba Lycopi, amber, oil of badian and cinnamon oil.The seed of cowherb, pool in side
Blue, amber dissipating bind promoting blood circulation and removing blood stasis；Radix Astragali QI invigorating, strengthen the effect of promoting blood circulation；CORTEX PHELLODENDRI AMURENE heat-clearing and damp-drying drug；Wind-damp dispelling pointed at both ends, subduing inflammation；
Dandelion clearing heat, detoxicating, dispelling dampness；Plantain seed is sweet in flavor and cold in property, promoting diuresis for stranguria, excreting dampness antidiarrheal；Chinese cassia tree, activating yang of Chinese anise are turbid；Entirely
Eliminating dampness and heat, the work(of blood stasis-eliminating and stagnation-dissipating are played altogether in side.
At present, qianlietong tablets be mainly used in the hot stasis of blood pent up it is lower it is burnt caused by light, the moderate retention of urine, symptoms include urination is not smooth, uroflow
Attenuate, frequent urination, can be with urgent urination, odynuria or pain in the back；Prostatitis and hyperplasia of prostate are shown in above-mentioned patient.
Prostatitis only has small number of patients to have acute medical history, shows as chronic, recurrent more and passes through.I types and II types forefront
Adenositis main pathogenic is pathogenic infection, and pathogen invades prostate with urine, causes to infect.Type III pathogenesis is not
Bright, teiology is sufficiently complex, extensive dispute be present.Most scholars think that its Etiological is probably pathogenic infection, work(of urinating
Energy obstacle, psychologic factors, neuroendocrine factor, immunoreaction abnormity, oxidative stress theory, lower urinary tract epithelium function barrier
Hinder.IV types lack the research of related pathogenesis, may be identical with the part cause and onset of disease mechanism of type III.
Study of incident mechanism about hyperplasia of prostate is a lot of, and functional testis must be possessed by being currently known hyperplasia of prostate
Ball and age increase by two conditions.In recent years it is also noted that smoking, obesity and excessive drinking, family history, ethnic group and geographical environment are with before
The relation that row gland hyperplasia occurs.
, may be related to the change of gene and the definite cause of disease of prostate cancer is not yet clear and definite so far.Such as androgen receptor body phase
The change of correlation gene can cause the risk of prostate cancer to increase；Male with BRCA1 genes suffers from the danger of prostate cancer
Property is 3 times of no BRCA1 genes male；And the exception of P53 genes and high-level, high aggressive prostate cancer are closely related.
The change of gene may also be related to the environmental factor such as diet.Gene alteration is more, and the danger for suffering from prostate cancer is bigger.
It can be proved based on current research, prostatitis, hyperplasia of prostate and prostate cancer are 3 kinds of prostate respectively
Disease because 3 pathogenesis are different, between there is no inevitable contact.
On therapeutic action of the qianlietong tablets to prostate cancer there is not yet research report.
The content of the invention
Based on this, it is necessary to provide a kind of application of Chinese medicine composition in the medicine for preparing treatment prostate cancer.
A kind of Chinese medicine composition prepare treatment prostate cancer medicine in application, the Chinese medicine composition it is effective into
Divide and be mainly prepared by the raw material of following parts by weight：
300~500 parts of the seed of cowherb, 350~580 parts of the Radix Astragali, 200~300 parts of plantain seed, 250~420 parts of CORTEX PHELLODENDRI AMURENE,
250~420 parts pointed at both ends, 250~420 parts of dandelion, 250~420 parts of Herba Lycopi, 55~95 parts of amber, cinnamon oil 0.7~1.2
Part, 1.2~2 parts of oil of badian.
In one of the embodiments, the active ingredient of the Chinese medicine composition is mainly prepared by the raw material of following parts by weight
Form：
380~420 parts of the seed of cowherb, 450~480 parts of the Radix Astragali, 250~280 parts of plantain seed, 310~350 parts of CORTEX PHELLODENDRI AMURENE,
310~350 parts pointed at both ends, 310~350 parts of dandelion, 310~350 parts of Herba Lycopi, 70~80 parts of amber, 0.9~1 part of cinnamon oil,
1.5~1.7 parts of oil of badian.
In one of the embodiments, the active ingredient of the Chinese medicine composition is mainly prepared by the raw material of following parts by weight
Form：
400 parts of the seed of cowherb, 464 parts of the Radix Astragali, 264 parts of plantain seed, 336 parts of CORTEX PHELLODENDRI AMURENE, 336 parts pointed at both ends, dandelion 336
Part, 336 parts of Herba Lycopi, 75 parts of amber, 0.93 part of cinnamon oil, 1.67 parts of oil of badian.
In one of the embodiments, the medicine includes the Chinese medicine composition and pharmaceutically acceptable auxiliary material.
In one of the embodiments, the formulation of the medicine is oral liquid, pill, granule, capsule, tablet, drop
Ball, injection or powder.
In one of the embodiments, the formulation of the medicine is tablet.
Compared with prior art, the invention has the advantages that：
It is mainly the seed of cowherb the invention provides active component, the Radix Astragali, plantain seed, CORTEX PHELLODENDRI AMURENE is pointed at both ends, dandelion,
Application of the Chinese medicine composition of Herba Lycopi, amber, cinnamon oil and oil of badian in the medicine for preparing treatment prostate cancer.Pass through
Drug efficacy study is found：Medicine containing above-mentioned Chinese medicine composition is respectively provided with one to prostate gland cancer cell such as PC-3,22RV1, DU145
Fixed inhibitory action is especially more obvious to PC-3 inhibition.Therefore above-mentioned Chinese medicine composition has treatment prostate
The effect of cancer, the new application of the Chinese medicine composition is thus provided, also provide new medicine for treatment prostate cancer.
Brief description of the drawings
Fig. 1 is influence experimental result of the qianlietong tablets to PC-3 tumor bearing nude mice body weight；
Fig. 2 is qianlietong tablets to PC-3 tumor bearing nude mices tumor weight and inhibition rate of tumor growth experimental result.
Embodiment
Chinese medicine composition answering in the medicine of preparation treatment prostate cancer below in conjunction with specific embodiment to the present invention
With being described in further detail.
Embodiment 1
A kind of Chinese medicine composition of the present embodiment, its active ingredient are prepared by the raw material of following weight：
Seed of cowherb 400g, Radix Astragali 464g, plantain seed 264g, CORTEX PHELLODENDRI AMURENE 336g, 336g pointed at both ends, dandelion 336g, pool
Blue 336g, amber 75g, cinnamon oil 0.88mL (0.93g), oil of badian 1.7mL (1.67g).
Formulation can be made as oral liquid, pill, particle by adding pharmaceutically acceptable auxiliary material in above-mentioned Chinese medicine composition
Agent, capsule, tablet, dripping pill, the medicine of injection or powder.
Embodiment 2
The present embodiment is application study of the Chinese medicine composition described in embodiment 1 in the medicine for preparing treatment prostate cancer.
1st, purpose：Qianlietong tablets is studied to inside prostate cancer and extracorporeal extracorporeal suppression
2nd, test sample
2.1 title：Qianlietong tablets：Including Chinese medicine composition described in embodiment 1, referring specifically to People's Republic of China's medicine
Allusion quotation》2015 editions one；
2.2 numbering：TC153236；
2.3 lot number：V00028；
2.4 character：Sheet；
2.5 specification：0.34g/ pieces, 108 pieces/bottle；
2.6 the date of manufacture：20150627；
2.7 valid until：201805；
2.8 source：Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd.；
2.9 preservation condition：Sealing.
3rd, reference substance
3.1 title：Flutamide piece；
3.1 numbering：MC15044；
3.1 lot number：150902；
3.1 character：Yellowish color chips；
3.1 valid until：201808；
3.1 source：ShangHai Fudan Fuhua Pharmaceutical Co., Ltd；
3.1 preservation condition：Shading, it is enclosed in and dries place's preservation.
4th, experiment solvent：Deionized water, Guangdong Medical Lab Animal Center's self-control.
5th, experimental animal and cell
5.1 Contained Serum anticancer experiment in vitro
5.1.1 kind strain：KM mouse
5.1.2 rank：SPF levels；
5.1.3 quantity and sex：25, male；
5.1.4 experiment starts body weight：21.6~26.0g；
5.1.5, unit is provided：Guangdong Medical Lab Animal Center.
Anti-tumor experiment in 5.2 bodies
5.2.1 kind strain：BALB/c nude mices；
5.2.2 rank：Cleaning grade；
5.2.3 quantity and sex：80, male；
5.2.4 animal orders week old：4~6 weeks；
5.2.5, unit is provided：Guangdong Medical Lab Animal Center；Production licence number：SCXK (Guangdong) 2013-0002.
The certification of fitness number：Mouse 44007200024982, nude mice 44007200027975.
5.3 recognition methods：Mouse uses hair decoration method, mouse is numbered using saturation picric acid, in Mice Body
The hair of table different parts applies specking point, to show jack per station.It is naked with mouse skin dyeing and cage tool dualism number marker recognition
Mouse is marked, to show jack per station using toe method is cut by different toes.With nude mice toe mark and cage tool dualism number mark
Identification.
5.4 select reason：Pharmacological experimental methodology and client provide data.
5.5 feeding management：Above animal is raised dynamic in Guangdong Medical Lab Animal Center SPF level Animal Houses, experiment
Thing uses credit number：SYXK (Guangdong) 2013-0002.Animal feeding condition：5/small case, group support.Using 10h:14h round the clock between
Disconnected illumination；Receptacle condition remains stable, with the reliability of guarantee test result.Ad lib drink water, pellet and
Drinking water provides by Guangdong Medical Lab Animal Center.
5.6 quarantine：To buying 3~5d of animal quarantine, observation 1 time, it is found that unsound animal is rejected immediately daily, quarantines
After end, animal carries out cell inoculation.
5.7 experimental cell systems：
5.7.1 species and source：PC-3, Human Prostate Cancer Cells, from Zhongshan University's cell bank；DU145 people forefront
Adenocarcinoma cell, from the American Type Culture Collection committee of Chinese Academy of Sciences cell bank；22RV1 Human Prostate Cancer Cells, source
In the American Type Culture Collection committee of Chinese Academy of Sciences cell bank.
5.7.2 condition of culture：37 DEG C, 5%CO2, from DMEM basal mediums, add 10% hyclone, 1% pair
It is anti-.
6th, major experimental instrument and reagent
6.1 major experimental instruments：JEA3001 electronic balances, precision 0.1g, Shanghai Pu Chun metrical instruments Co., Ltd；
BS224S electronic analytical balances：German Sartouius, sensibility reciprocal：0.1mg.
6.2 main agents：RPMI1640 nutrient solutions, lot number 8116019, valid until：201701, GIBCO Products；
DMEM basal mediums, lot number 8115160,8115348, valid until：201606/201610, GIBCO Products；Serum,
Lot number：12211119th, NCS00615-2, valid until：201709th, 202006, GIBCO, AusGeneX Products；It is dual anti-,
Lot number：1124A14,5122301001100, valid until：201512nd, 201703, Hangzhou Ji promise, GENVIEW Products；
0.25 trypsase-EDTA, lot number：57300101100th, 61110101100, GENVIEW Products；PBS, lot number：
5AB001100, valid until：201712, BOSTER Products.MTT：Lot number：M7905, MP Products.
7th, packet and dose design
7.1 Contained Serums prepare experiment：SPF level KM mouse, are randomly divided into vehicle control group, positive controls, Traditional Chinese proprietary medicine Qianlietong for curing prostatosis
Piece group, 5/group.Corresponding given the test agent is given according to the gavage of table 1, vehicle control group mouse stomach gives isometric 0.5%
CMC-Na, 1 time/d, continuous 3d.1h after last dose, eye socket takes blood, 3000 turns/min, separates serum, standby.
The preparation of the qianlietong tablets Contained Serum of table 1
The packet of 7.2 PC-3 tumor bearing nude mices：PC-3 Prostatic cancer cell lines 80 nude mices of subcutaneous vaccination are chosen, treat tumour
Grow to 100mm3During left and right, choose 50 tumor sizes similar in mice with tumor be randomly divided into 5 groups, test sample height (4.08g/kg),
In (2.04g/kg), low (1.02g/kg) dosage group, model (solvent) control (0.5%CMC-Na) group and positive controls
(125mg/kg).Gavage volume is 20mL/kg.
8th, experimental method
8.1 qianlietong tablets Contained Serum anticancer experiment in vitro
Tested from 3 plants of prostate cancer tumor cells, the cell medium culture matched, passage, pass through sight
It is in good condition to examine determination, includes experiment.Three plants of tumour cells turn are commissioned to train foster, when exponential phase is in, digestion counts, system
Into cell suspension, adjustment cell density is 1 × 104Individual/ml, in 96 orifice plate bed board cultures, per the μ L of hole 100.37 DEG C, 5%CO2, training
After supporting 24, former culture medium is discarded, every kind of cell is separately added into the Contained Serum culture medium of 200 μ L respective concentrations.Positive controls
Serum final concentration with vehicle control group is 10%, and final concentration of Traditional Chinese proprietary medicine Qianlietong for curing prostatosis group Contained Serum is respectively 5%, 10%, 20%.
Culture 48 hours, 20 μ L, 5mg/ml MTT is added per hole, continue supernatant discarding after culture 4h, add 150 μ LDMSO per hole, fully
Concussion mixes, and with ELIASA, is detected in 570nm and 630nm.
Anti-tumor experiment inside 8.2 qianlietong tabletses
8.2.1 solvent is prepared：Weighing 0.5gCMCNa adds deionized water to match somebody with somebody to obtain 100mL0.5%CMCNa suspensions.
8.2.2 positive control is prepared：A piece of Flutamide slice lapping is taken to match somebody with somebody obtained 4mL plus CMCNa suspensions are stated to fine powder
Concentration is 6.25mg/mL Flutamide suspension.
8.2.3 test sample is prepared：High dose takes 6 qianlietong tabletses, after grinding, 0.5%CMCNa suspensions is added, to 10mL
Mix, it is 204mg/mL high dose Traditional Chinese proprietary medicine Qianlietong for curing prostatosis suspensions to obtain concentration, and middle dosage takes 3 qianlietong tabletses, after grinding, is added above-mentioned
CMCNa suspensions, mixed to 10mL, it is 102mg/mL middle dosage Traditional Chinese proprietary medicine Qianlietong for curing prostatosis suspensions to obtain concentration, and low dosage takes 3 Traditional Chinese proprietary medicine Qianlietong for curing prostatosis
Piece, after grinding, add above-mentioned CMCNa suspensions and mixed to 20mL, it is 51mg/mL low dosage Traditional Chinese proprietary medicine Qianlietong for curing prostatosis suspensions to obtain concentration.
8.2.4 according to Vitro Experimental Results, PC-3 prostate cancer tumor cells is chosen and are cultivated, treat cell growth to right
Number phase, digestion count, and cell suspension, adjustment cell density to 2 × 10 is made7Individual/ml, it is subcutaneously injected in the left shoulder back of nude mice thin
Born of the same parents' suspension, every 0.1ml.Treat that tumour length to 5mm or so, chooses more uniform 50 mice with tumor of tumor size, according to tumour
Size is randomly divided into 5 groups, model (solvent) control group, positive controls, the high, medium and low dosage group of test sample, 10/group.For examination
Product height (4.08g/kg), in (2.04g/kg), low (1.02g/kg) dosage group, model (solvent) control (0.5%CMC-Na) group
With positive controls (125mg/kg).Gavage volume is 0.2ml/10g, 1 times/day, continuous 32 days.
8.2.5 observation animal state, and being recorded daily.
8.2.6 the weight of animals is claimed weekly, weekly major diameter, the minor axis of measurement tumour 3 times.
8.2.7 at the end of testing, neck dislocation is put to death, and is peeled off tumour and is weighed, takes pictures.Calculate inhibition rate of tumor growth.
8.2.8 tumor weight：At the end of experiment, completely strip tumour and weigh, calculate inhibition rate of tumor growth：
9th, statistical analysis and result judgement
9.1 statistical analysis：It is arranged side by side that statistical disposition is carried out to indexs such as the body weight of each group nude mice, gross tumor volume, tumor weights
Table explanation；Initial data is represented with mean plus-minus standard deviationModel (solvent) is carried out using one-way analysis of variance
Significance test of difference between control group and other administration groups.
9.2 result judgement：Administration group inhibition rate of tumor growth >=40%, and it is effective to be statistically analyzed P ＜ 0.05.
10th, result and discussion
10.1 cell in vitro strain screening experiments：(being shown in Table 2)
The qianlietong tablets Contained Serum of table 2 is to three kinds of prostate cancer anti tumor activity in vitro
Qianlietong tablets Contained Serum (concentration 20%, 10%, 5%) is respectively 47.6% to PC-3 cell survival rates,
87.2%th, 112.9%；Survival rate to 22RV1 cells is respectively 90.9%, 89.6%, 85.3%, and DU145 cells are deposited
Motility rate is respectively 82.7%, 106.3%, 100.4%.
10.2 animal ordinary circumstances are observed：Each group animal carries out general clinical setting observation daily, is showed no abnormal response,
Normal-weight increases (being shown in Table 3, Fig. 1).
The qianlietong tablets of table 3 to PC-3 tumor bearing nude mice body weight influence (N=10,)
10.3 tumor growth rates and gross tumor volume (being shown in Table 4 and Fig. 2)
The qianlietong tablets of table 4 is to PC-3 tumor bearing nude mices tumor weight and inhibition rate of tumor growth
Note：Compared with model (solvent) control group, * represents that P ＜ 0.05, * * represent P ＜ 0.01
Compared with model control group, test sample low dose group tumor weight, which has no, significantly reduces (P>0.05), tumour growth
Inhibiting rate 18.5%, the middle and high dosage group of test sample and positive controls tumor weight significantly reduce (P<0.05), tumour growth presses down
Rate processed is respectively 40.3%, 23.8%, 62.6%.And test sample middle dose group and positive controls inhibition rate of tumor growth are more than
40%.
Test sample high dose group dosage is higher, and drug concentration is larger, may influence its absorption.
Conclusion：Under this experiment condition, qianlietong tablets Contained Serum is more obvious to PC-3 Carbazole alkaloids effect.2.04g/
Kg qianlietong tablets has certain inhibitory action to PC-3 prostate cancer transplanted tumor in nude mice.
Each technical characteristic of embodiment described above can be combined arbitrarily, to make description succinct, not to above-mentioned reality
Apply all possible combination of each technical characteristic in example to be all described, as long as however, the combination of these technical characteristics is not deposited
In contradiction, the scope that this specification is recorded all is considered to be.
Embodiment described above only expresses the several embodiments of the present invention, and its description is more specific and detailed, but simultaneously
Can not therefore it be construed as limiting the scope of the patent.It should be pointed out that come for one of ordinary skill in the art
Say, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to the protection of the present invention
Scope.Therefore, the protection domain of patent of the present invention should be determined by the appended claims.
Claims (6)
1. a kind of application of Chinese medicine composition in the medicine for preparing treatment prostate cancer, the active ingredient of the Chinese medicine composition
Mainly it is prepared by the raw material of following parts by weight：
300~500 parts of the seed of cowherb, 350~580 parts of the Radix Astragali, 200~300 parts of plantain seed, 250~420 parts of CORTEX PHELLODENDRI AMURENE, two
250~420 parts of point, 250~420 parts of dandelion, 250~420 parts of Herba Lycopi, 55~95 parts of amber, 0.7~1.2 part of cinnamon oil, eight
1.2~2 parts of erect hypecoum oil.
2. application according to claim 1, it is characterised in that the active ingredient of the Chinese medicine composition mainly by weighing as follows
The raw material of amount part is prepared：
380~420 parts of the seed of cowherb, 450~480 parts of the Radix Astragali, 250~280 parts of plantain seed, 310~350 parts of CORTEX PHELLODENDRI AMURENE, two
310~350 parts of point, 310~350 parts of dandelion, 310~350 parts of Herba Lycopi, 70~80 parts of amber, 0.9~1 part of cinnamon oil are anistree
1.5~1.7 parts of fennel oil.
3. application according to claim 2, it is characterised in that the active ingredient of the Chinese medicine composition mainly by weighing as follows
The raw material of amount part is prepared：
400 parts of the seed of cowherb, 464 parts of the Radix Astragali, 264 parts of plantain seed, 336 parts of CORTEX PHELLODENDRI AMURENE, 336 parts pointed at both ends, 336 parts of dandelion,
336 parts of Herba Lycopi, 75 parts of amber, 0.93 part of cinnamon oil, 1.67 parts of oil of badian.
4. according to the application described in claim any one of 1-3, it is characterised in that the medicine include the Chinese medicine composition with
And pharmaceutically acceptable auxiliary material.
5. according to the application described in claim any one of 1-3, it is characterised in that the formulation of the medicine be oral liquid, pill,
Granule, capsule, tablet, dripping pill, injection or powder.
6. application according to claim 5, it is characterised in that the formulation of the medicine is tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610805445.6A CN107802689A (en) | 2016-09-05 | 2016-09-05 | Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610805445.6A CN107802689A (en) | 2016-09-05 | 2016-09-05 | Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107802689A true CN107802689A (en) | 2018-03-16 |
Family
ID=61575895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610805445.6A Pending CN107802689A (en) | 2016-09-05 | 2016-09-05 | Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107802689A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN104225033A (en) * | 2013-06-15 | 2014-12-24 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatic cancer |
-
2016
- 2016-09-05 CN CN201610805445.6A patent/CN107802689A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778358A (en) * | 2004-11-24 | 2006-05-31 | 河北以岭医药研究院有限公司 | Medicine for treating prostatic accrementition and its preparation |
| CN104225033A (en) * | 2013-06-15 | 2014-12-24 | 石家庄以岭药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatic cancer |
Non-Patent Citations (1)
| Title |
|---|
| 国家药典委员会编: "《中华人民共和国药典:2015年版.一部》", 30 June 2015 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103222988B (en) | A kind of American-cockroach-extract and its preparation method and application | |
| CN101485463A (en) | Natural product composing prescription with various health-care efficacies | |
| CN101199683A (en) | Chinese medicine for treating skin disease and preparing method thereof | |
| CN102657841A (en) | Ginger phenols extract preparation and preparation method thereof | |
| CN103169737A (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN102670977B (en) | Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition | |
| CN101653508A (en) | Chinese medicinal compound preparation for treating prostatauxe and chronic prostatitis | |
| CN101380359B (en) | Bone-building capsules and preparation method thereof | |
| CN107802689A (en) | Application of the Chinese medicine composition in the medicine for preparing treatment prostate cancer | |
| CN102078507B (en) | Uncaria-containing composition with anti-aging function | |
| CN104082537B (en) | For promoting ablactational baby pig growth and improving the medicated feed additive of immune function | |
| CN102747030B (en) | H2O2-inducing NIH-3T3 cell aging model | |
| Abon | Anthelmintic efficacy of tuba (Croton tiglium L.) seeds on the gastrointestinal parasites of native chickens (Gallus domesticus) | |
| CN107412282B (en) | Application of ardisia nigripes extract in preparation of anti-prostate cancer drugs | |
| CN101700394A (en) | Pharmaceutical composite for curing colon cancer and preparing method thereof | |
| Shakeri et al. | Comparison efficacy of oral Peganum harmala seed versus tamsulosin on pain relief and expulsion of renal and ureteral stones; a randomized clinical trial. | |
| CN105983021A (en) | External-use medicinal composition as well as preparation method and applications thereof | |
| CN103110930A (en) | Lead-removing composition and preparation method thereof | |
| CN101485791B (en) | Application of Ampelopsis grossedentata total flavone in preparing medicament for preventing and treating adverse reaction of tumor chemoradiotherapy | |
| CN102302589A (en) | Chinese medicinal composition for treating diarrhea irritable bowel syndrome and preparation method thereof | |
| CN101708271B (en) | Chinese medicament for treating esophageal cancer | |
| Iqbal et al. | Phytochemistry, Laxative, Prokinetic and Spasmolytic Verification of Withania somnifera (L.) Dunal Using In-Vitro, In-Vivo and In-Silico Approaches | |
| CN105663453A (en) | Preparation method of anti-pestilence and fever powder | |
| CN118078916A (en) | Chinese herbal compound preparation for treating lung cancer and application thereof | |
| CN104147557A (en) | Shogaol extract soft capsule and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180316 |
|
| RJ01 | Rejection of invention patent application after publication |